`
`
`
`UNITED STATES PATENT AND TRADEMARK OFFICE
`______________________
`BEFORE THE PATENT TRIAL AND APPEAL BOARD
`______________________
`
`ELI LILLY AND COMPANY
`Petitioner
`v.
`TEVA PHARMACEUTICALS INTERNATIONAL GMBH
`Patent Owner
`______________________
`
`IPR2018-01426
`Patent No. 9,890,211
`______________________
`
`PETITIONER’S UPDATED EXHIBIT LIST AS OF SEPTEMBER 10, 2019
`
`
`
`
`
`
`
`
`
`
`
`
`
`Further to 37 C.F.R. § 42.63(e), Petitioner Eli Lilly and Company hereby
`
`IPR2018-01426
`Patent No. 9,890,211
`
`submits a current listing of Lilly Exhibits.
`
`Exhibit
`
`Description
`
`Ex. 1001
`
`U.S. Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`
`Ex. 1002
`
`Reserved
`
`Ex. 1003
`
`Reserved
`
`Ex. 1004
`
`Reserved
`
`Ex. 1005
`
`Reserved
`
`Ex. 1006
`
`Reserved
`
`Ex. 1007
`
`Reserved
`
`Ex. 1008
`
`Reserved
`
`Ex. 1009
`
`Reserved
`
`Ex. 1010
`
`Reserved
`
`Ex. 1011
`
`Reserved
`
`Ex. 1012
`
`Ex. 1013
`
`Declaration of Andrew Charles, M.D. (U.S. Patent No.
`9,890,211)
`
`Declaration of Alain P. Vasserot (U.S. Patent No.
`9,890,211)
`
`Ex. 1014
`
`Reserved
`
`Ex. 1015
`
`Reserved
`
`Ex. 1016
`
`Reserved
`
`1
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1017
`
`Reserved
`
`Ex. 1018
`
`Reserved
`
`Ex. 1019
`
`Teva’s U.S. Provisional Application No. 60/736,623
`
`Ex. 1020
`
`Teva’s PCT Application No. WO 2007/054809
`
`Ex. 1021
`
`Ex. 1022
`
`Tan et al., “Demonstration of the Neurotransmitter Role of
`Calcitonin Gene-Related Peptides (CGRP) by
`Immunoblockade with Anti-CGRP Monoclonal
`Antibodies,” Br. J. Pharmacol. (1994) 111: 703-710
`
`Tan et al., “Calcitonin Gene-Related Peptide as an
`Endogenous Vasodilator: Immunoblockade Studies in vivo
`with an Anti-Calcitonin Gene-Related Peptide Monoclonal
`Antibody and Its Fab’ Fragment,” Clinical Sci. (1995) 89:
`565-573
`
`Ex. 1023
`
`Queen et al., U.S. Patent No. 6,180,370
`
`Ex. 1024
`
`Ex. 1025
`
`Doods et al., “Pharmacological Profile of BIBN4096BS,
`the First Selective Small Molecule CGRP Antagonist,” Br.
`J. Pharmacol. (2000) 129: 420-423
`
`Olesen et al., “Calcitonin Gene-Related Peptide Receptor
`Antagonist BIBN 4096 BS for the Acute Treatment of
`Migraine,” N. Engl. J. Med. (2004) 350: 1104-1110
`
`Ex. 1026
`
`Sveinsson, International Publication No. WO 2004/014351
`
`Ex. 1027
`
`Salmon et al., U.S. Patent Application Publication No. US
`2002/0162125
`
`Ex. 1028
`
`De Lacharriere et al., U.S. Patent No. 6,344,438
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`2
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1029
`
`Ex. 1030
`
`Ex. 1031
`
`Olesen et al., “S26 CGRP Antagonism as a New
`Therapeutic Principle in Acute Migraine,” Neuropeptides
`(2004) 38: 110-131
`
`Arndt et al., “CGRP Antagonism — A Valid New Concept
`for the Treatment of Migraine Pain,” Neuropeptides (2004)
`38: 110-131
`
`Arulmani et al., “Calcitonin Gene-related Peptide and Its
`Role in Migraine Pathophysiology,” Eur. J. Pharmacol.
`(2004) 143: 315-330
`
`Ex. 1031A Arulmani et al., “Calcitonin Gene-related Peptide and Its
`Role in Migraine Pathophysiology,” Eur. J. Pharmacol.
`(2004) 143: 315-330
`
`Ex. 1032
`
`Frobert et al., “A Sensitive Sandwich Enzyme
`Immunoassay for Calcitonin Gene-Related Peptide
`(CGRP): Characterization and Application,” Peptides
`(1999) 20: 275-284
`
`Ex. 1032A Frobert et al., “A Sensitive Sandwich Enzyme
`Immunoassay for Calcitonin Gene-Related Peptide
`(CGRP): Characterization and Application,” Peptides
`(1999) 20: 275-284
`
`Ex. 1033 Wong et al., “Monoclonal Antibody to Rat α-CGRP:
`Production, Characterization, and in vivo
`Immunoneutralization Activity,” Hybridoma (1993) 12: 93-
`106
`
`Ex. 1033A Wong et al., “Monoclonal Antibody to Rat α-CGRP:
`Production, Characterization, and in vivo
`Immunoneutralization Activity,” Hybridoma (1993) 12: 93-
`106
`
`
`
`
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`3
`
`
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Exhibit
`
`Ex. 1034
`
`Rist et al., “From Micromolar to Nanomolar Affinity: A
`Systematic Approach to Identify the Binding Site of CGRP
`at the Human Calcitonin Gene-Related Peptide 1
`Receptor,” J. Med. Chem. (1998) 41: 117-123
`
`Ex. 1034A Rist et al., “From Micromolar to Nanomolar Affinity: A
`Systematic Approach to Identify the Binding Site of CGRP
`at the Human Calcitonin Gene-Related Peptide 1
`Receptor,” J. Med. Chem. (1998) 41: 117-123
`
`Ex. 1035
`
`Edvinsson and Hargreaves, The Headaches 289-299 (3rd
`ed. 2006)
`
`Ex. 1035A Edvinsson and Hargreaves, The Headaches 289-299 (3rd
`ed. 2006)
`
`Ex. 1036
`
`Reserved
`
`Ex. 1037
`
`Reserved
`
`Ex. 1038 Mason et al., “Release of the Predicted Calcitonin Gene-
`Related Peptide from Cultured Rat Trigeminal Ganglion
`Cells,” Nature (1984) 308: 653-655
`
`Ex. 1038A Mason et al., “Release of the Predicted Calcitonin Gene-
`Related Peptide from Cultured Rat Trigeminal Ganglion
`Cells,” Nature (1984) 308: 653-655
`
`Ex. 1039
`
`Brain et al., “Calcitonin Gene-Related Peptide is a Potent
`Vasodilator,” Nature (1985) 313: 54-56
`
`Ex. 1039A Brain et al., “Calcitonin Gene-Related Peptide is a Potent
`Vasodilator,” Nature (1985) 313: 54-56
`
`Ex. 1040
`
`Arulmozhi et al., “Migraine: Current Concepts and
`Emerging Therapies,” Vascular Pharmacol. (2005) 43:
`176-187
`
`4
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1040A Arulmozhi et al., “Migraine: Current Concepts and
`Emerging Therapies,” Vascular Pharmacol. (2005) 43:
`176-187
`
`Ex. 1041
`
`Durham, “CGRP-Receptor Antagonists — A Fresh
`Approach to Migraine Therapy?” N. Engl. Med. (2004)
`350(11): 1073-1075
`
`Ex. 1041A Durham, “CGRP-Receptor Antagonists — A Fresh
`Approach to Migraine Therapy?” N. Engl. Med. (2004)
`350(11): 1073-1075
`
`Ex. 1042
`
`Ex. 1042A
`
`Iovino et al., “Safety, Tolerability and Pharmacokinetics of
`BIBN 4096 BS, the First Selective Small Molecule
`Calcitonin Gene-related Peptide Receptor Antagonist,
`Following Single Intravenous Administration in Healthy
`Volunteers,” Cephalalgia (2004) 24: 645-656
`
`Iovino et al., “Safety, Tolerability and Pharmacokinetics of
`BIBN 4096 BS, the First Selective Small Molecule
`Calcitonin Gene-related Peptide Receptor Antagonist,
`Following Single Intravenous Administration in Healthy
`Volunteers,” Cephalalgia (2004) 24: 645-656
`
`Ex. 1043
`
`Goadsby et al., “Vasoactive Peptide Release in the
`Extracerebral Circulation of Humans During Migraine
`Headache,” Annals of Neurology (1990) 28(2): 183-187
`
`Ex. 1043A Goadsby et al., “Vasoactive Peptide Release in the
`Extracerebral Circulation of Humans During Migraine
`Headache,” Annals of Neurology (1990) 28(2): 183-187
`
`Ex. 1044
`
`Goadsby and Edvinsson, “The Trigeminovascular System
`and Migraine: Studies Characterizing Cerebrovascular and
`Neuropeptide Changes Seen in Humans and Cats,” Annals
`of Neurology (1993) 33(1): 48-56
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`5
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1044A Goadsby and Edvinsson, “The Trigeminovascular System
`and Migraine: Studies Characterizing Cerebrovascular and
`Neuropeptide Changes Seen in Humans and Cats,” Annals
`of Neurology (1993) 33(1): 48-56
`
`Ex. 1045
`
`Ex. 1045A
`
`Ex. 1046
`
`Juhasz et al., “NO-induced Migraine Attack: Strong
`Increase in Plasma Calcitonin Gene-Related Peptide
`(CGRP) Concentration and Negative Correlation with
`Platelet Serotonin Release,” Pain (2003) 106: 461-470
`
`Juhasz et al., “NO-induced Migraine Attack: Strong
`Increase in Plasma Calcitonin Gene-Related Peptide
`(CGRP) Concentration and Negative Correlation with
`Platelet Serotonin Release,” Pain (2003) 106: 461-470
`
`Goadsby and Edvinsson, “Human in vivo Evidence for
`Trigeminovascular Activation in Cluster Headache:
`Neuropeptide Changes and Effects of Acute Attacks
`Therapies,” Brain (1994) 117: 427-434
`
`Ex. 1046A Goadsby and Edvinsson, “Human in vivo Evidence for
`Trigeminovascular Activation in Cluster Headache:
`Neuropeptide Changes and Effects of Acute Attacks
`Therapies,” Brain (1994) 117: 427-434
`
`Ex. 1047
`
`Lassen et al., “CGRP May Play a Causative Role in
`Migraine,” Cephalagia (2002) 22: 54-61
`
`Ex. 1047A Lassen et al., “CGRP May Play a Causative Role in
`Migraine,” Cephalagia (2002) 22: 54-61
`
`Ex. 1048
`
`Louis et al., “Antibodies to Calcitonin-Gene Related
`Peptide Reduce Inflammation Induced by Topical Mustard
`Oil But Not that Due to Carrageenin in the Rat,”
`Neuroscience Letters (1989) 102: 257-260
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`6
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1048A Louis et al., “Antibodies to Calcitonin-Gene Related
`Peptide Reduce Inflammation Induced by Topical Mustard
`Oil But Not that Due to Carrageenin in the Rat,”
`Neuroscience Letters (1989) 102: 257-260
`
`Ex. 1049
`
`Dockray et al., “Immunoneutralization Studies with
`Calcitonin Gene-Related Peptide,” Annals of N.Y. Acad.
`Scis. (1992) 258-267
`
`Ex. 1049A Dockray et al., “Immunoneutralization Studies with
`Calcitonin Gene-Related Peptide,” Annals of N.Y. Acad.
`Scis. (1992) 258-267
`
`Ex. 1050
`
`Louis et al., “The Role of Substance P and Calcitonin
`Gene-Related Peptide in Neurogenic Plasma Extravasation
`and Vasodilation in the Rat,” Neuroscience (1989) 32(3):
`581-586
`
`Ex. 1050A Louis et al., “The Role of Substance P and Calcitonin
`Gene-Related Peptide in Neurogenic Plasma Extravasation
`and Vasodilation in the Rat,” Neuroscience (1989) 32(3):
`581-586
`
`Ex. 1051
`
`Ex. 1052
`
`Sigma-Aldrich, Biochemicals & Reagents for Life Science
`Research 350-352 (2004)
`
`Escott and Brain, “Effect of a Calcitonin Gene-Related
`Peptide Antagonist (CGRP8-37) on Skin Vasodilatation and
`Oedema Induced by Stimulation of the Rat Saphenous
`Nerve,” Br. J. Pharmacol. (1993) 110: 772-776
`
`Ex. 1052A Escott and Brain, “Effect of a Calcitonin Gene-Related
`Peptide Antagonist (CGRP8-37) on Skin Vasodilatation and
`Oedema Induced by Stimulation of the Rat Saphenous
`Nerve,” Br. J. Pharmacol. (1993) 110: 772-776
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`X
`
`7
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1053
`
`Reserved
`
`Ex. 1054
`
`Reserved
`
`Ex. 1055
`
`Andrew et al., “Monoclonal Antibodies Distinguishing α
`and β Forms of Calcitonin Gene-Related Peptide,” J.
`Immunol. Methods (1990) 154: 87-94
`
`Ex. 1055A Andrew et al., “Monoclonal Antibodies Distinguishing α
`and β Forms of Calcitonin Gene-Related Peptide,” J.
`Immunol. Methods (1990) 154: 87-94
`
`Ex. 1056
`
`Reichert et al., “Monoclonal Antibody Successes in the
`Clinic,” Nature Biotechnol. (2005) 23: 1073-1078
`
`Ex. 1056A Reichert et al., “Monoclonal Antibody Successes in the
`Clinic,” Nature Biotechnol. (2005) 23: 1073-1078
`
`Ex. 1057
`
`Projan et al., “Small Molecules for Small Minds? The Case
`for Biologic Pharmaceuticals,” Expert Opin. Biol. Ther.
`(2004) 4: 1345-1350
`
`Ex. 1057A Projan et al., “Small Molecules for Small Minds? The Case
`for Biologic Pharmaceuticals,” Expert Opin. Biol. Ther.
`(2004) 4: 1345-1350
`
`Ex. 1058
`
`Janeway et al., Immunobiology 93-122 (5th ed. 2001)
`
`Ex. 1059
`
`Janeway et al., Immunobiology 123-154 (5th ed. 2001)
`
`Ex. 1060
`
`Janeway et al., Immunobiology 341-380 (5th ed. 2001)
`
`Ex. 1061
`
`Van Valen et al., “Calcitonin Gene-Related Peptide
`(CGRP) Receptors are Linked to Cyclic Adenosine
`Monophosphate Production in SK-N-MC Human
`Neuroblastoma Cells,” Neuroscience Letters (1990) 119:
`195-198
`
`
`
`
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`
`
`
`
`8
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1061A Van Valen et al., “Calcitonin Gene-Related Peptide
`(CGRP) Receptors are Linked to Cyclic Adenosine
`Monophosphate Production in SK-N-MC Human
`Neuroblastoma Cells,” Neuroscience Letters (1990) 119:
`195-198
`
`Ex. 1062
`
`Kipriyanov and Le Gall, “Generation and Production of
`Engineered Antibodies,” Mol. Biotechnol. (2004) 26: 39-60
`
`Ex. 1062A Kipriyanov and Le Gall, “Generation and Production of
`Engineered Antibodies,” Mol. Biotechnol. (2004) 26: 39-60
`
`Ex. 1063
`
`Elgert, Immunology: Understanding the Immune System
`58-78 (1st ed. 1996)
`
`Ex. 1064 Wright and Morrison, “Effect of Glycosylation on
`Antibody Function: Implications for Genetic Engineering,”
`Trends Biotechnol. (1997) 15: 26-32
`
`Ex. 1064A Wright and Morrison, “Effect of Glycosylation on
`Antibody Function: Implications for Genetic Engineering,”
`Trends Biotechnol. (1997) 15: 26-32
`
`Ex. 1065
`
`Brüggemann et al., “Comparison of the Effector Functions
`of Human Immunoglobulins Using a Matched Set of
`Chimeric Antibodies,” J. Exp. Med. (1987) 166: 1351-1361
`
`Ex. 1065A Brüggemann et al., “Comparison of the Effector Functions
`of Human Immunoglobulins Using a Matched Set of
`Chimeric Antibodies,” J. Exp. Med. (1987) 166: 1351-1361
`
`Ex. 1066
`
`Presta, “Selection, Design, and Engineering of Therapeutic
`Antibodies,” J. Allergy Clin. Immunol. (2005) 116: 731-
`736
`
`X
`
`
`
`X
`
`
`
`
`
`X
`
`
`
`X
`
`
`
`9
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1066A Presta, “Selection, Design, and Engineering of Therapeutic
`Antibodies,” J. Allergy Clin. Immunol. (2005) 116: 731-
`736
`
`Ex. 1067
`
`Tao and Morrison, “Studies of Aglycosylated Chimeric
`Mouse-Human IgG: Role of Carbohydrate in the Structure
`and Effector Functions Mediated by the Human IgG
`Constant Region,” J. Immunol. (1989) 143: 2595-2601
`
`Ex. 1067A Tao and Morrison, “Studies of Aglycosylated Chimeric
`Mouse-Human IgG: Role of Carbohydrate in the Structure
`and Effector Functions Mediated by the Human IgG
`Constant Region,” J. Immunol. (1989) 143: 2595-2601
`
`Ex. 1068 Maynard and Georgiou, “Antibody Engineering,” Annu.
`Rev. Biomed. Eng. (2000) 2: 339-376
`
`Ex. 1068A Maynard and Georgiou, “Antibody Engineering,” Annu.
`Rev. Biomed. Eng. (2000) 2: 339-376
`
`Ex. 1069
`
`Chester and Hawkins, “Clinical Issues in Antibody
`Design,” Trends Biotechnol. (1995) 13: 294-300
`
`Ex. 1069A Chester and Hawkins, “Clinical Issues in Antibody
`Design,” Trends Biotechnol. (1995) 13: 294-300
`
`Ex. 1070
`
`Kim et al., “Antibody Engineering for the Development of
`Therapeutic Antibodies,” Mol. Cells (2005) 20: 17-29
`
`Ex. 1070A Kim et al., “Antibody Engineering for the Development of
`Therapeutic Antibodies,” Mol. Cells (2005) 20: 17-29
`
`Ex. 1071
`
`Gavilondo and Larrick, “Antibody Engineering at the
`Millennium,” BioTechniques (2000) 29: 128-145
`
`Ex. 1071A Gavilondo and Larrick, “Antibody Engineering at the
`Millennium,” BioTechniques (2000) 29: 128-145
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`10
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1072
`
`Khazaeli et al., “Human Immune Response to Monoclonal
`Antibodies,” J. Immunother. (1994) 15: 42-52
`
`Ex. 1072A Khazaeli et al., “Human Immune Response to Monoclonal
`Antibodies,” J. Immunother. (1994) 15: 42-52
`
`Ex. 1073
`
`Carter, “Improving the Efficacy of Antibody-Based Cancer
`Therapies,” Nature Revs. Cancer (2001) 1: 118-129
`
`Ex. 1073A Carter, “Improving the Efficacy of Antibody-Based Cancer
`Therapies,” Nature Revs. Cancer (2001) 1: 118-129
`
`Ex. 1074
`
`Kettleborough et al., “Humanization of a Mouse
`Monoclonal Antibody by CDR-Grafting: The Importance
`of Framework Residues on Loop Conformation,” Protein
`Eng. (1991) 4: 773-783
`
`Ex. 1074A Kettleborough et al., “Humanization of a Mouse
`Monoclonal Antibody by CDR-Grafting: The Importance
`of Framework Residues on Loop Conformation,” Protein
`Eng. (1991) 4: 773-783
`
`Ex. 1075
`
`Queen et al., “A Humanized Antibody that Binds to the
`Interleukin 2 Receptor,” Proc. Natl. Acad. Sci. USA (1989)
`86: 10029-10033
`
`Ex. 1075A Queen et al., “A Humanized Antibody that Binds to the
`Interleukin 2 Receptor,” Proc. Natl. Acad. Sci. USA (1989)
`86: 10029-10033
`
`Ex. 1076
`
`Friend et al., “Phase I Study of an Engineered
`Aglycosylated Humanized CD3 Antibody in Renal
`Transplant Rejection,” Transplantation (1999) 68: 1632-
`1637
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`11
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1076A Friend et al., “Phase I Study of an Engineered
`Aglycosylated Humanized CD3 Antibody in Renal
`Transplant Rejection,” Transplantation (1999) 68: 1632-
`1637
`
`Ex. 1077
`
`Brekke and Sandlie, “Therapeutic Antibodies for Human
`Diseases at the Dawn of the Twenty-First Century,” Nature
`Revs. Drug Discov. (2003) 2: 52-62
`
`Ex. 1077A Brekke and Sandlie, “Therapeutic Antibodies for Human
`Diseases at the Dawn of the Twenty-First Century,” Nature
`Revs. Drug Discov. (2003) 2: 52-62
`
`Ex. 1078
`
`Cole et al., “Human IgG2 Variants of Chimeric Anti-CD3
`are Nonmitogenic to T cells,” J. Immunol. (1997) 159:
`3613-3621
`
`Ex. 1078A Cole et al., “Human IgG2 Variants of Chimeric Anti-CD3
`are Nonmitogenic to T cells,” J. Immunol. (1997) 159:
`3613-3621
`
`Ex. 1079
`
`Huse et al., International Publication No. WO 2001/27160
`
`Ex. 1080
`
`Reserved
`
`Ex. 1081
`
`Reserved
`
`Ex. 1082
`
`Vater et al., “Short Bioactive Spiegelmers to Migraine-
`Associated Calcitonin Gene-Related Peptide Rapidly
`Identified by a Novel Approach: Tailored-SELEX,”
`Nucleic Acids Res. (2003) 31: 1-7
`
`Ex. 1083
`
`Lisa Djavadi-Ohaniance et al., Antibody Engineering: A
`Practical Approach 77-117 (1st ed. 1996)
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`
`
`
`
`
`
`Ex. 1083A Lisa Djavadi-Ohaniance et al., Antibody Engineering: A
`Practical Approach 77-117 (1st ed. 1996)
`
`X
`
`12
`
`
`
`Exhibit
`
`Ex. 1084
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Van Regenmortal et al., “Improving the Quality of
`BIACORE-Based Affinity Measurements,” Dev. Biol.
`(Basel) (2003) 112: 141-151
`
`Ex. 1084A Van Regenmortal et al., “Improving the Quality of
`BIACORE-Based Affinity Measurements,” Dev. Biol.
`(Basel) (2003) 112: 141-151
`
`Ex. 1085
`
`GE Healthcare, Biacore Sensor Surface Handbook (2005)
`
`Ex. 1086
`
`Kelley, “Thermodynamics of Protein-Protein Interaction
`Studied by Using BIAcore and Single-Site Mutagenesis,”
`Methods (1994) 6: 111-120
`
`Ex. 1086A Kelley, “Thermodynamics of Protein-Protein Interaction
`Studied by Using BIAcore and Single-Site Mutagenesis,”
`Methods (1994) 6: 111-120
`
`Ex. 1087
`
`Ex. 1087A
`
`Johnstone et al., “The Effect of Temperature on the
`Binding Kinetics and Equilibrium Constants of Monoclonal
`Antibodies to Cell Surface Antigens,” Mol. Immunol.
`(1990) 27: 327-333
`
`Johnstone et al., “The Effect of Temperature on the
`Binding Kinetics and Equilibrium Constants of Monoclonal
`Antibodies to Cell Surface Antigens,” Mol. Immunol.
`(1990) 27: 327-333
`
`Ex. 1088
`
`Carter, “Potent Antibody Therapeutics by Design,” Nature
`Revs. Immunol. (2006) 6: 343-357
`
`Ex. 1088A Carter, “Potent Antibody Therapeutics by Design,” Nature
`Revs. Immunol. (2006) 6: 343-357
`
`Ex. 1089
`
`Goadsby et al., “Migraine — Current Understanding and
`Treatment,” N. Engl. J. Med. (2002) 346: 257-270
`
`13
`
`
`
`X
`
`
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1089A Goadsby et al., “Migraine — Current Understanding and
`Treatment,” N. Engl. J. Med. (2002) 346: 257-270
`
`Ex. 1090
`
`Petersen et al., “Inhibitory Effect of BIBN4096BS on
`Cephalic Vasodilation Induced by CGRP or Transcranial
`Electrical Stimulation in the Rat,” Br. J. Pharm. (2004)
`143: 697-704
`
`Ex. 1090A Petersen et al., “Inhibitory Effect of BIBN4096BS on
`Cephalic Vasodilation Induced by CGRP or Transcranial
`Electrical Stimulation in the Rat,” Br. J. Pharm. (2004)
`143: 697-704
`
`Ex. 1091
`
`Purves et al., Neuroscience 763-773 (3rd ed. 2004)
`
`Ex. 1092
`
`Reserved
`
`Ex. 1093
`
`Reserved
`
`Ex. 1094
`
`Reserved
`
`Ex. 1095
`
`Conner et al., “Interaction of Calcitonin-Gene-Related
`Peptide with Its Receptors,” Biochemistry Society
`Transactions (2002) 30(4): 451-455
`
`Ex. 1095A Conner et al., “Interaction of Calcitonin-Gene-Related
`Peptide with Its Receptors,” Biochemistry Society
`Transactions (2002) 30(4): 451-455
`
`Ex. 1096 Wimalawansa, “Calcitonin Gene-Related Peptide and Its
`Receptors: Molecular Genetics, Physiology,
`Pathophysiology, and Therapeutic Potentials,” Endocrine
`Revs. (1996) 17(5): 533-585
`
`X
`
`
`
`X
`
`
`
`
`
`
`
`
`
`
`
`X
`
`
`
`14
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1097 Williamson et al., “Intravital Microscope Studies on the
`Effects of Neurokinin Agonists and Calcitonin Gene-
`Related Peptide on Dural Vessel Diameter in the
`Anaesthetized Rat,” Cephalalgia (1997) 17: 518-524
`
`Ex. 1098
`
`Hong et al., “Pharmacological Coupling and Functional
`Role for CGRP Receptors in the Vasodilation of Rat Pial
`Arterioles,” Am. J. Physiol. (1996) 270: H317-H323
`
`Ex. 1099
`
`Reserved
`
`Ex. 1100
`
`Reserved
`
`Ex. 1101
`
`Jones et al., “Replacing the Complementarity-Determining
`Regions in a Human Antibody with Those from a Mouse,”
`Nature (1986) 321: 522-525
`
`Ex. 1101A
`
`Jones et al., “Replacing the Complementarity-Determining
`Regions in a Human Antibody with Those from a Mouse,”
`Nature (1986) 321: 522-525
`
`Ex. 1102
`
`Reserved
`
`Ex. 1103
`
`Ex. 1104
`
`Ex. 1105
`
`Tysabri® Letter from the Food and Drug Administration
`(2004)
`
`Pollack, “F.D.A. Approves a Multiple Sclerosis Drug,”
`New York Times (November 24, 2004)
`
`Sandborn and Yednock, “Novel Approaches to Treating
`Inflammatory Bowel Disease: Targeting Alpha-4 Integrin,”
`Am. J. Gastroenterol (2003) 98: 2372-2382
`
`
`
`
`
`
`
`
`
`
`
`X
`
`
`
`
`
`
`
`
`
`Ex. 1105A Sandborn and Yednock, “Novel Approaches to Treating
`Inflammatory Bowel Disease: Targeting Alpha-4 Integrin,”
`Am. J. Gastroenterol (2003) 98: 2372-2382
`
`X
`
`15
`
`
`
`Exhibit
`
`Ex. 1106
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Hamann P.R., Berger M.S. (2002) Mylotarg. In: Pagé M.
`(eds) Tumor Targeting in Cancer Therapy. Cancer Drug
`Discovery and Development. Humana Press, Totowa, NJ.
`
`Ex. 1106A Hamann P.R., Berger M.S. (2002) Mylotarg. In: Pagé M.
`(eds) Tumor Targeting in Cancer Therapy. Cancer Drug
`Discovery and Development. Humana Press, Totowa, NJ.
`
`Ex. 1107
`
`Knight et al., “Pharmacodynamic Enhancement of the Anti-
`Platelet Antibody Fab Abciximab by Site-Specific
`Pegylation,” Platelets (2004) 15: 409-418
`
`Ex. 1107A Knight et al., “Pharmacodynamic Enhancement of the Anti-
`Platelet Antibody Fab Abciximab by Site-Specific
`Pegylation,” Platelets (2004) 15: 409-418
`
`Ex. 1108
`
`RituxanTM (rituximab) Prescribing Information (1997)
`
`Ex. 1109
`
`Reff et al., “Depletion of B Cells in vivo by a Chimeric
`Mouse Human Monoclonal Antibody to CD20,” Blood
`(1994) 83: 435-445
`
`Ex. 1109A Reff et al., “Depletion of B Cells in vivo by a Chimeric
`Mouse Human Monoclonal Antibody to CD20,” Blood
`(1994) 83: 435-445
`
`Ex. 1110
`
`Tsurushita et al., “Design of Humanized Antibodies: From
`anti-Tac to Zenapax,” Methods (2005) 36: 69-83
`
`Ex. 1110A Tsurushita et al., “Design of Humanized Antibodies: From
`anti-Tac to Zenapax,” Methods (2005) 36: 69-83
`
`Ex. 1111
`
`Simulect® (basiliximab) Prescribing Information (1998)
`
`Ex. 1112
`
`Synagis® (palivizumab) EMA Scientific Discussion (2004)
`
`16
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1113 Wu et al., “Ultra-Potent Antibodies Against Respiratory
`Syncytial Virus: Effects of Binding Kinetics and Binding
`Valence on Viral Neutralization,” J. Mol. Biol. (2005) 350:
`126-144
`
`Ex. 1113A Wu et al., “Ultra-Potent Antibodies Against Respiratory
`Syncytial Virus: Effects of Binding Kinetics and Binding
`Valence on Viral Neutralization,” J. Mol. Biol. (2005) 350:
`126-144
`
`Ex. 1114 Maini and Feldmann, “How Does Infliximab Work in
`Rheumatoid Arthritis?” Arthritis Res. (2002) 4: S22-S28
`
`Ex. 1115
`
`Herceptin® (trastuzumab) Prescribing Information (1998)
`
`Ex. 1116
`
`Carter et al., “Humanization of an Anti-p185HER2 Antibody
`for Human Cancer Therapy,” Proc. Natl. Acad. Sci. USA
`(1992) 89: 4285-4289
`
`Ex. 1116A Carter et al., “Humanization of an Anti-p185HER2 Antibody
`for Human Cancer Therapy,” Proc. Natl. Acad. Sci. USA
`(1992) 89: 4285-4289
`
`Ex. 1117 MabCampath® (alemtuzumab) EMA Scientific Discussion
`(2005)
`
`Ex. 1118
`
`Ex. 1119
`
`ZevalinTM (ibritumomab tiuxetan) Prescribing Information
`(2001)
`
`Santora et al., “Characterization of Noncovalent
`Complexes of Recombinant Human Monoclonal Antibody
`and Antigen Using Cation Exchange, Size Exclusion
`Chromatography, and BIAcore,” Anal. Biochem. (2001)
`299: 119-129
`
`
`
`X
`
`
`
`
`
`
`
`X
`
`
`
`
`
`
`
`17
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1119A Santora et al., “Characterization of Noncovalent
`Complexes of Recombinant Human Monoclonal Antibody
`and Antigen Using Cation Exchange, Size Exclusion
`Chromatography, and BIAcore,” Anal. Biochem. (2001)
`299: 119-129
`
`Ex. 1120
`
`Shields et al, “Inhibition of Allergic Reactions with
`Antibodies to IgE,” Int. Arch. Allergy Immunol. (1995)
`107: 308-312
`
`Ex. 1120A Shields et al, “Inhibition of Allergic Reactions with
`Antibodies to IgE,” Int. Arch. Allergy Immunol. (1995)
`107: 308-312
`
`Ex. 1121
`
`Cardarelli et al., “Binding to CD20 by Anti-B1 antibody or
`F(ab')(2) is Sufficient for Induction of Apoptosis in B-Cell
`Lines,” Cancer Immunol. Immunother. (2002) 51: 15-24
`
`Ex. 1121A Cardarelli et al., “Binding to CD20 by Anti-B1 antibody or
`F(ab')(2) is Sufficient for Induction of Apoptosis in B-Cell
`Lines,” Cancer Immunol. Immunother. (2002) 51: 15-24
`
`Ex. 1122 Werther et al., “Humanization of an Anti-lymphocyte
`Function-Associated Antigen (LFA)-l Monoclonal
`Antibody and Reengineering of the Humanized Antibody
`for Binding to Rhesus LFA-1,” J. Immunol. (1996) 157:
`4986-4995.
`
`Ex. 1122A Werther et al., “Humanization of an Anti-lymphocyte
`Function-Associated Antigen (LFA)-l Monoclonal
`Antibody and Reengineering of the Humanized Antibody
`for Binding to Rhesus LFA-1,” J. Immunol. (1996) 157:
`4986-4995.
`
`X
`
`
`
`X
`
`
`
`X
`
`
`
`X
`
`18
`
`
`
`Exhibit
`
`Ex. 1123
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Goldstein et al., “Biological Efficacy of a Chimeric
`Antibody to the Epidermal Growth Factor Receptor in a
`Human Tumor Xenograft Model,” Clin. Cancer. Res.
`(1995) 1: 1311-1318
`
`
`
`X
`
`
`
`
`
`X
`
`
`
`X
`
`
`
`
`
`Ex. 1123A Goldstein et al., “Biological Efficacy of a Chimeric
`Antibody to the Epidermal Growth Factor Receptor in a
`Human Tumor Xenograft Model,” Clin. Cancer. Res.
`(1995) 1: 1311-1318
`
`Ex. 1124
`
`Avastin® (bevacizumab) EMA Scientific Discussion (2005)
`
`Ex. 1125
`
`Ferrara et al., “Discovery and Development of
`Bevacizumab, an Anti-VEGF Antibody for Treating
`Cancer,” Nature Rev. Drug Discov. (2004) 3: 391-400
`
`Ex. 1125A Ferrara et al., “Discovery and Development of
`Bevacizumab, an Anti-VEGF Antibody for Treating
`Cancer,” Nature Rev. Drug Discov. (2004) 3: 391-400
`
`Ex. 1126
`
`Léger et al., “Humanization of a Mouse Antibody against
`Human Alpha-4 Integrin: A Potential Therapeutic for the
`Treatment of Multiple Sclerosis,” Hum. Antibodies (1997)
`8: 3-16
`
`Ex. 1126A Léger et al., “Humanization of a Mouse Antibody against
`Human Alpha-4 Integrin: A Potential Therapeutic for the
`Treatment of Multiple Sclerosis,” Hum. Antibodies (1997)
`8: 3-16
`
`Ex. 1127
`
`Lilly’s U.S. Provisional Application No. 60/753,004
`
`Ex. 1128
`
`U.S. Provisional Application No. 60/711,950
`
`19
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1129 Wu et al., “Stepwise in vitro Affinity Maturation of
`Vitaxin, an αvβ3-Specific Humanized mAb,” Proc. Natl.
`Acad. Sci. USA (1998) 95: 6037-42
`
`Ex. 1130
`
`Janeway et al., Immunobiology 626-627 (5th ed. 2001)
`
`Ex. 1131
`
`Reserved
`
`Ex. 1132
`
`Reserved
`
`Ex. 1133
`
`Reserved
`
`Ex. 1134
`
`Pisegna et al., U.S. Patent Application Publication No.
`2004/0110170
`
`Ex. 1135
`
`Reserved
`
`Ex. 1136
`
`September 5, 2013 Teva’s Response to Office Action (U.S.
`Patent No. 8,597,649 prosecution history)
`
`Ex. 1137
`
`Reserved
`
`Ex. 1138
`
`Reserved
`
`Ex. 1139
`
`Reserved
`
`Ex. 1140
`
`Reserved
`
`Ex. 1141
`
`Reserved
`
`Ex. 1142 Yang et al., “CDR Walking Mutagenesis for the Affinity
`Maturation of a Potent Human Anti-HIV-1 Antibody into
`the Picomolar Range,” J. Mol. Biol. (1995) 254: 392-403
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Ex. 1142A Yang et al., “CDR Walking Mutagenesis for the Affinity
`Maturation of a Potent Human Anti-HIV-1 Antibody into
`the Picomolar Range,” J. Mol. Biol. (1995) 254: 392-403
`
`X
`
`20
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1143
`
`Reserved
`
`Ex. 1144
`
`Reserved
`
`Ex. 1145
`
`Reserved
`
`Ex. 1146
`
`Reserved
`
`Ex. 1147
`
`Reserved
`
`Ex. 1148
`
`Reserved
`
`Ex. 1149
`
`Reserved
`
`Ex. 1150
`
`Reserved
`
`Ex. 1151
`
`Reserved
`
`Ex. 1152
`
`Reserved
`
`Ex. 1153
`
`Reserved
`
`Ex. 1154
`
`Reserved
`
`Ex. 1155
`
`Reserved
`
`Ex. 1156
`
`Reserved
`
`Ex. 1157
`
`Reserved
`
`Ex. 1158
`
`Reserved
`
`Ex. 1159
`
`Reserved
`
`Ex. 1160
`
`Reserved
`
`Ex. 1161
`
`Reserved
`
`Ex. 1162
`
`Reserved
`
`21
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1163
`
`Reserved
`
`Ex. 1164
`
`Reserved
`
`Ex. 1165
`
`Reserved
`
`Ex. 1166
`
`Reserved
`
`Ex. 1167
`
`Reserved
`
`Ex. 1168
`
`Reserved
`
`Ex. 1169
`
`Reserved
`
`Ex. 1170
`
`Reserved
`
`Ex. 1171
`
`Reserved
`
`Ex. 1172
`
`Reserved
`
`Ex. 1173
`
`Reserved
`
`Ex. 1174
`
`Reserved
`
`Ex. 1175
`
`Reserved
`
`Ex. 1176
`
`Reserved
`
`Ex. 1177
`
`Reserved
`
`Ex. 1178
`
`Reserved
`
`Ex. 1179
`
`Reserved
`
`Ex. 1180
`
`Reserved
`
`Ex. 1181
`
`Reserved
`
`Ex. 1182
`
`Reserved
`
`22
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1183
`
`Reserved
`
`Ex. 1184
`
`Reserved
`
`Ex. 1185
`
`Reserved
`
`Ex. 1186
`
`Reserved
`
`Ex. 1187
`
`Reserved
`
`Ex. 1188
`
`Reserved
`
`Ex. 1189
`
`Reserved
`
`Ex. 1190
`
`Reserved
`
`Ex. 1191
`
`Reserved
`
`Ex. 1192
`
`Reserved
`
`Ex. 1193
`
`Reserved
`
`Ex. 1194
`
`Reserved
`
`Ex. 1195
`
`Reserved
`
`Ex. 1196 May 5, 2017 Application Data Sheet (U.S. Patent No.
`9,890,211 prosecution history)
`
`Ex. 1197
`
`Ex. 1198
`
`Ex. 1199
`
`June 26, 2017 Office Action (U.S. Patent No. 9,890,211
`prosecution history)
`
`August 23, 2017 Teva’s Response to Office Action (U.S.
`Patent No. 9,890,211 prosecution history)
`
`August 23, 2017 Terminal Disclaimers (U.S. Patent No.
`9,890,211 prosecution history)
`
`23
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1200 May 26, 2017 Information Disclosure Statement (U.S.
`Patent No. 9,890,211 prosecution history)
`
`Ex. 1201
`
`Ex. 1202
`
`August 23, 2017 Information Disclosure Statement (U.S.
`Patent No. 9,890,211 prosecution history)
`
`October 27, 2017 Information Disclosure Statement (U.S.
`Patent No. 9,890,211 prosecution history)
`
`Ex. 1203
`
`Reserved
`
`Ex. 1204
`
`Reserved
`
`Ex. 1205
`
`Reserved
`
`Ex. 1206
`
`Reserved
`
`Ex. 1207
`
`Reserved
`
`Ex. 1208
`
`Reserved
`
`Ex. 1209
`
`Reserved
`
`Ex. 1210
`
`Reserved
`
`Ex. 1211
`
`Reserved
`
`Ex. 1212
`
`Reserved
`
`Ex. 1213
`
`Reserved
`
`Ex. 1214
`
`Reserved
`
`Ex. 1215
`
`Reserved
`
`Ex. 1216
`
`Reserved
`
`Ex. 1217
`
`Reserved
`
`24
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1218
`
`Reserved
`
`Ex. 1219
`
`Reserved
`
`Ex. 1220
`
`Reserved
`
`Ex. 1221
`
`Reserved
`
`Ex. 1222
`
`Reserved
`
`Ex. 1223
`
`Reserved
`
`Ex. 1224
`
`Reserved
`
`Ex. 1225
`
`Reserved
`
`Ex. 1226
`
`Reserved
`
`Ex. 1227
`
`Reserved
`
`Ex. 1228
`
`Reserved
`
`Ex. 1229
`
`Reserved
`
`Ex. 1230
`
`Reserved
`
`Ex. 1231
`
`Reserved
`
`Ex. 1232
`
`Reserved
`
`Ex. 1233
`
`Reserved
`
`Ex. 1234
`
`Reserved
`
`Ex. 1235
`
`Reserved
`
`Ex. 1236
`
`Reserved
`
`Ex. 1237
`
`Reserved
`
`25
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1238
`
`Reserved
`
`Ex. 1239
`
`Reserved
`
`Ex. 1240 Messlinger et al., “Inhibition of Neurogenic Blood Flow
`Increases in the Rat Cranial Dura Mater by a CGRP-
`Binding Spiegelmer,” Cephalalgia (2005) 25: 923 (F022)
`
`Ex. 1241
`
`Reserved
`
`Ex. 1242
`
`Reserved
`
`Ex. 1243
`
`Reserved
`
`Ex. 1244
`
`Reserved
`
`Ex. 1245
`
`Reserved
`
`Ex. 1246
`
`Reserved
`
`Ex. 1247
`
`Covell et al., “Pharmacokinetics of Monoclonal
`Immunoglobulin G1, F(ab’)2, and Fab’ in Mice,” Cancer
`Res. (1986) 46: 3969-3978
`
`Ex. 1248
`
`Reserved
`
`Ex. 1249
`
`Reserved
`
`Ex. 1250
`
`Reserved
`
`Ex. 1251
`
`Reserved
`
`Ex. 1252
`
`Reserved
`
`Ex. 1253
`
`Reserved
`
`Ex. 1254
`
`Reserved
`
`26
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Exhibit
`
`Description
`
`IPR2018-01426
`Patent No. 9,890,211
`
`Served
`Not
`Filed
`
`Ex. 1255
`
`Reserved
`
`Ex. 1256
`
`Reser
Accessing this document will incur an additional charge of $.
After purchase, you can access this document again without charge.
Accept $ Charge
Still Working On It
This document is taking longer than usual to download. This can happen if we need to contact the court directly to obtain the document and their servers are running slowly.
Give it another minute or two to complete, and then try the refresh button.
A few More Minutes ... Still Working
It can take up to 5 minutes for us to download a document if the court servers are running slowly.
Thank you for your continued patience.
This document could not be displayed.
We could not find this document within its docket. Please go back to the docket page and check the link. If that does not work, go back to the docket and refresh it to pull the newest information.
Your account does not support viewing this document.
You need a Paid Account to view this document. Click here to change your account type.
Your account does not support viewing this document.
Set your membership
status to view this document.
With a Docket Alarm membership, you'll
get a whole lot more, including:
- Up-to-date information for this case.
- Email alerts whenever there is an update.
- Full text search for other cases.
- Get email alerts whenever a new case matches your search.
One Moment Please
The filing “” is large (MB) and is being downloaded.
Please refresh this page in a few minutes to see if the filing has been downloaded. The filing will also be emailed to you when the download completes.
Your document is on its way!
If you do not receive the document in five minutes, contact support at support@docketalarm.com.
Sealed Document
We are unable to display this document, it may be under a court ordered seal.
If you have proper credentials to access the file, you may proceed directly to the court's system using your government issued username and password.
Access Government Site
